Melanocortin receptors and energy homeostasis

Current Opinion in Endocrinology and Diabetes

Volumn 12, Issue 3, 2005, Pages 205-210

  Coll, Anthony P ^a   Challis, Benjamin G ^a   Yeo, Giles S H ^a   Farooqi, I Sadaf ^a   O'Rahilly, Stephen ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Energy homeostasis; MC3 R; MC4 R; Melanocortins; Pro opiomelanocortin

Indexed keywords

ALPHA INTERMEDIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ; GLUCOSE; HORMONE ANTAGONIST; HORMONE RECEPTOR STIMULATING AGENT; LEPTIN; LIGAND; MELANIN CONCENTRATING HORMONE; MELANOCORTIN; MELANOCORTIN 3 RECEPTOR; MELANOCORTIN 4 RECEPTOR; MELANOCORTIN ANTAGONIST; MELANOCORTIN RECEPTOR AGONIST; PROOPIOMELANOCORTIN; UNCLASSIFIED DRUG;

ACETYLATION; AMINO TERMINAL SEQUENCE; BRAIN STEM; ENERGY; ETHNIC GROUP; GENE MUTATION; GLUCOSE TRANSPORT; HOMEOSTASIS; HORMONE ACTION; HUMAN; NERVE CELL; NONHUMAN; OBESITY; PHENOTYPE; PROTEIN DOMAIN; REVIEW; RISK FACTOR; SATIETY; SIGNAL TRANSDUCTION;

EID: 20444365181     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.med.0000162078.80344.35     Document Type: Review

References (50)

1. Bertagna X. Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am 1994; 23:467-485.
2. Cone RD. The central melanocortin system and energy homeostasis. Trends Endocrinol Metab 1999; 10:211-216.
3. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
4. Yeo GS, Farooqi IS, Aminian S, et al. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 1998; 20:111-112.
5. Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 1998; 20:113-114.
6. Farooqi IS, Keogh JM, Yeo GS, et al. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003; 348:1085-1095.
7. Huszar D, Lynch CA, Fairchild-Huntress V, et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88:131-141.
8. Ste Marie L, Miura GI, Marsh DJ, et al. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci U S A 2000; 97:12339-12344.
9. Butler AA, Marks DL, Fan W, et al. Melanocortin-4 receptor is required for acute homeostatic responses to increased dietary fat. Nat Neurosci 2001; 4:605-611.
10. Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26:97-102.
11. Butler AA, Kesterson RA, Khong K, et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000; 141:3518-3521.
12. Boston BA, Blaydon KM, Varnerin J, Cone RD. Independent and additive effects of central POMC and leptin pathways on murine obesity. Science 1997; 278:1641-1644.
13. Marsh DJ, Hollopeter G, Husiar D, et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 1999; 21:119-122.
14. Balthasar N, Coppari R, McMinn J, et al. Leptin receptor signaling in POMC neurons is required for normal body weight homeostasis. Neuron 2004; 42:983-991. An excellent study investigating a key question in energy homeostasis. The techniques outlined will prove to be powerful tools in further delineating the neural circuits mediating leptin's effect.
15. Challis BG, Coll AP, Yeo GS, et al. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc Natl Acad Sci U S A 2004; 101:4695-4700. Evidence that loss of a single copy of Pomc is sufficient to render mice susceptible to obesity on a high fat diet and so highlighting this locus as a site for gene-environment interactions predisposing to obesity.
16. Pritchard LE, Turnbull AV, White A. Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity. J Endocrinol 2002; 172:411-421.
17. Guo L, Munzberg H, Stuart RC, et al. N-acetylation of hypothalamic alpha-melanocyte-stimulating hormone and regulation by leptin. Proc Natl Acad Sci U S A 2004; 101:11797-11802. Data demonstrating that leptin induces hypothalamic N-acetyltransferase activity, resulting in increased levels of the highly stable and potent MSH analogue. N-acetylated-α-MSH. The identification of the enzymes involved may provide novel targets for therapeutic intervention.
18. Gutierrez-Juarez R, Obici S, Rossetti L. Melanocortin-independent effects of leptin on hepatic glucose fluxes. J Biol Chem 2004; 279:49704-49715. Building upon their previous data linking the leptin-melanocortin system and glucose homeostasis, this group has now carried out a highly detailed study into the mechanisms by which leptin can stimulate gluconeogenesis and inhibit glycolysis.
19. Moran TH. Cholecystokinin and satiety: current perspectives. Nutrition 2000; 16:858-865.
20. Fan W, Ellacott KL, Halatchev IG, et al. Cholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system. Nat Neurosci 2004; 7:335-336. Evidence that the melanocortin system may integrate short-term satiety signals as well as long-term adipostatic signals.
21. Batterham RL, Cowley MA, Small CJ, et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418:650-654.
22. Batterham RL, Cohen MA, Ellis SM, et al. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 2003; 349:941-948.
23. Martin NM, Small CJ, Sajedi A, et al. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int J Obes Relat Metab Disord 2004; 28:886-893. In addition to demonstrating that Agouti mice are sensitive to PYY 3-36, results showing that there may be a role for the melanocortin system in mediating ghrelin's effects.
24. Halatchev IG, Ellacott KL, Fan W, Cone RD. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004; 145:2585-2590. Insightful observations into the need to acclimatize mice to handling and injections in order to reliably achieve a reduction in food intake with PYY 3-36.
25. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380:243-247.
26. Hanada R, Nakazato M, Matsukura S, et al. Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system. Biochem Biophys Res Commun 2000; 268:88-91.
27. Kernie SG, Liebl DJ, Parada LF. BDNF regulates eating behavior and locomotor activity in mice. EMBO J 2000; 19:1290-1300.
28. Rios M, Fan G, Fekete C, et al. Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. Mol Endocrinol 2001; 15:1748-1757.
29. N'akagawa T, Ono-Kishino M, Sugaru E, et al. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Diabetes Metab Res Rev 2002; 18:185-191.
30. Xu B, Goulding EH, Zang K, et al. Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003; 6:736-742.
31. Kas MJ, Tiesjema B, van Dijk G, et al. Induction of brain region-specific forms of obesity by Agouti. J Neurosci 2004; 24:10176-10181. Data suggesting that the melanocortin system can regulate different adaptive strategies to alter an organism's energy balance.
32. Krude H, Biebermann H, Luck W, et al. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19:155-157.
33. Krude H, Biebermann H, Schnabel D, et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003; 88:4633-4640.
34. Ma L, Tataranni PA, Bogardus C, Baier LJ. Melanocortin 4 receptor gene variation is associated with severe obesity in Pima Indians. Diabetes 2004; 53:2696-2699.
35. Larsen LH, Echwald SM, Sorensen TI, et al. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab 2005; 90:219-224. An important contribution to the debate regarding the true prevalence of pathogenic MC4R variants in the general unselected population.
36. Lee YS, Poh LK, Loke KY. A novel melanocortin 3 receptor gene (MC3R) mutation associated with severe obesity. J Clin Endocrinol Metab 2002; 87:1423-1426.
37. Rached M, Buronfosse A, Begeot M, Penhoat A. Inactivation and intracellular retention of the human I183N mutated melanocortin 3 receptor associated with obesity. Biochim Biophys Acta 2004; 1689:229-234.
38. Tao YX, Segaloff DL. Functional characterization of melanocortin-3 receptor variants identify a loss-of-function mutation involving an amino acid critical for G protein-coupled receptor activation. J Clin Endocrinol Metab 2004; 89:3936-3942.
39. Yeo GS, Connie Hung CC, Rochford J, et al. A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004; 7:1187-1189. First report of a unique human syndrome of hyperphagic obesity.
40. Cai G, Cole SA, Bastarrachea-Sosa RA, et al. Quantitative trait locus determining dietary macronutrient intakes is located on human chromosome 2p22. Am J Clin Nutr 2004; 80:1410-1414. These results suggest that this chromosomal region might contribute to dietary macronutrient intakes and adiposity phenotypes in Mexican Americans.
41. Geller F, Reichwald K, Dempfle A, et al. Melanocortin-4 receptor gene variant 1103 is negatively associated with obesity. Am J Hum Genet 2004; 74:572-581.
42. Marks DL, Boucher N, Lanouette CM, et al. Ala67Thr polymorphism in the Agouti-related peptide gene is associated with inherited leanness in humans. Am J Med Genet A 2004; 126:267-271. First demonstration of an association between the presence of a putative recessive allele and a lean phenotype in an otherwise healthy human population.
43. Srinivasan S, Lubrano-Berthelier C, Govaerts C, et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 2004; 114:1158-1164. An investigation into obesity-associated mutations lying within the N-terminal (NT) domain of MC4-R which in vitro do not impair ligand binding. The results suggest a novel molecular mechanism potentially at work within the MC4-R.
44. Biebermann H, Krude H, Elsner A, et al. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 2003; 52:2984-2988.
45. Mandrika I, Petrovska R, Wikberg J. Melanocortin receptors form constitutive homo- and heterodimers. Biochem Biophys Res Commun 2005; 326:349-354.
46. Li G, Mobbs CV, Scarpace PJ. Central pro-opiomelanocortin gene delivery results in hypophagia, reduced visceral adiposity, and improved insulin sensitivity in genetically obese Zucker rats. Diabetes 2003; 52:1951-1957.
47. Savontaus E, Breen TL, Kim A, et al. Metabolic effects of transgenic melanocyte-stimulating hormone overexpression in lean and obese mice. Endocrinology 2004; 145:3881-3891. This report supports the notion that chronic activation of the melanocortin system may serve as an effective strategy for the treatment of obesity and impaired glucose tolerance.
48. Wessells H, Levine N, Hadley ME, et al. Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Meianotan II. Int J Impot Res 2000; 12(Suppl 4):S74-S79.
49. Rosen RC, Diamond LE, Earle DC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004; 16:135-142.
50. Vos TJ, Caracoti A, Che JL, et al. Identification of 2-[2-[2-(5-bromo-2- methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 2004; 47:1602-1604.